



HHS Public Access

Author manuscript

J Occup Environ Med. Author manuscript; available in PMC 2018 December 01.

Published in final edited form as:

J Occup Environ Med. 2017 December ; 59(Suppl 12): S28–S35. doi:10.1097/JOM.0000000000001124.

Longitudinal and Cross-sectional Analyses of Lung Function in Toluene Diisocyanate Production Workers

Mei Lin Wang, MD, MPH, Eileen Storey, MD, MPH, Laura D. Cassidy, PhD, MS, Brent Doney, PhD, MS, MPH, Patrick R. Conner, MD, James J. Collins, PhD, Michael Carson, DO, MPH, and Don Molenaar, MD

National Institute for Occupational Safety and Health, Morgantown, West Virginia (Drs Wang [former affiliation], Storey, Doney); Medical College of Wisconsin, Milwaukee, Wisconsin (Dr Cassidy); BASF-The Chemical Company, Florham Park, New Jersey (Dr Conner [former affiliation]); DOW Chemical Company, Midland, Michigan (Drs Collins, Carson [former affiliations]); Saginaw Valley State University, University City, Michigan (Dr Collins); and Covestro LLC (formerly known as Bayer MaterialScience LLC), Pittsburgh, Pennsylvania (Dr Molenaar [former affiliation]).

Abstract

Objective—The aim of this study was to investigate lung function among toluene diisocyanate (TDI) production workers.

Methods—One hundred ninety-seven U.S workers performed spirometry from 2006 through 2012. Results were compared within the study cohort and with U.S. population measures. A mixed-effects model assessed factors affecting repeated forced expiratory volume in 1 second (FEV₁) measurements.

Results—The cohort's mean FEV₁ and forced vital capacity (FVC) percent reference values, although greater than 90%, were significantly lower and the prevalence of abnormal spirometry (predominantly restrictive pattern) was significantly higher than in the U.S. population. Differences in lung function among workers with higher cumulative TDI exposure were in the direction of an exposure effect, but not significant.

Conclusion—We found little evidence of an adverse effect of TDI exposure on longitudinal spirometry in these workers. The association between TDI exposure and the increasing prevalence of a restrictive pattern needs further exploration.

Toluene diisocyanate (TDI) is recognized as a respiratory toxicant capable of causing pulmonary impairment and immunologic disturbances in exposed persons.¹ Since the 1950s,

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Address correspondence to: Eileen Storey, MD, MPH, Surveillance Branch, Respiratory Health Division, NIOSH/CDC, 1095 Willowdale Road MS HG900, Morgantown, WV 26508 (EStorey@cdc.gov).

The authors have no conflicts of interest to declare.

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.

FVC).¹⁵ The LLN approximated the one-sided 95% confidence limit for the expected value based on the NHANES III prediction equations. Percent reference values were determined using NHANES III spirometry data from healthy, nonsmoking individuals as the reference.¹⁵ The observed spirometry value from a participant was divided by the predicted value from the corresponding reference and then multiplied by 100.

Patterns of spirometry abnormality were defined as follows:

1. Obstructive abnormality was characterized by narrowing of the airways during exhalation leading to a decline in FEV_1/FVC and a disproportionate reduction in FEV_1 compared with FVC: $FEV_1/FVC < LLN$; $FVC > LLN$; and $FEV_1 < LLN$.
2. Restrictive abnormality was characterized by reduced lung compliance causing a decline in total lung capacity: $FEV_1/FVC > LLN$; and $FVC < LLN$.
3. Mixed abnormality was characterized by both obstructive and restrictive abnormalities: $FEV_1/FVC < LLN$; and $FVC < LLN$.

Statistical Analysis

Data analyses were performed using SAS 9.2 (SAS Institute, Cary, NC). Cross-sectional analyses included comparisons of %Ref values and the proportion of abnormal spirometry between the study population and the U.S. general population, and also within the study population. For the U.S. population, we used the NHANES combined 2007 to 2010 datasets collected by the National Center for Health Statistics (NCHS). For NHANES 2007 to 2010, study participants were selected using a complex, multistage, probability sampling design. Participants were interviewed in their homes and asked to attend an examination in the mobile examination center that included spirometry for those 6 to 79 years of age. NHANES 2007 to 2010 was approved by the NCHS Research Ethics Review Board. The NHANES website offers detailed information about the surveys.¹⁶

For the purpose of comparing the spirometry results for the TDI study participants with the U.S. general population, we used spirometry, demographic information, height, weight, and smoking history from NHANES 2007 to 2010, and documentation explaining the database from the NCHS website using the methods recommended by NCHS.¹⁷ Only those persons 20 to 69 years of age at the time of examination were included. Eight datasets were combined and converted to SAS datasets for further analysis and the proper sample weights were used according to NCHS analytic and reporting guidelines to account for the NHANES complex sample survey.¹⁸ SAS PROC SURVEYMEANS and SAS PROC SURVEYFREQ were used to obtain the variance estimations and 95% confidence intervals (95% CIs) for the means of spirometry indices and the proportions of abnormal lung function stratified by age, gender, race/ethnicity, and smoking status that accounted for weighting. Means obtained from the TDI study cohort and NHANES 2007 to 2010 were compared using the corresponding 95% CI obtained from NHANES 2007 to 2010. If the TDI mean fell into the NHANES 95% CI, there was no significant evidence of difference between the TDI study cohort and the U.S. general population.

Longitudinal rate of decline in an individual's FEV₁, often called "FEV₁ slope," was calculated for study participants by linear regression of FEV₁ measurements over time. The resulting FEV₁ slope was then used as the outcome variable in the two-stage analysis comparing average slopes across the various groups of interest within the study cohort, including age group, gender, race/ethnicity, smoking status, and TDI exposure categories. The cross-sectional comparisons of %Ref values of FEV₁, FVC, and FEV₁/FVC ratio were evaluated using *t* tests or analysis of variance (ANOVA). The comparisons of spirometry indices were also made within the TDI cohort, by age group, smoking status, and among four TDI exposure groups by quartiles of ml95.

Exposure Assessment

The development of exposure estimates is described in the study by Middendorf et al¹⁹ and those that are used in this paper are summarized here. Exposure assessment was conducted at the three plant locations. Employees who perform similar tasks that had the potential to produce similar time-weighted average (TWA) TDI exposures, based on detailed discussions of job descriptions, were grouped into plant-level similar exposure groups (Plant/SEGs). Air samples representing shift length duration TWA exposures were collected. Samples were collected and analyzed using the Covestro LLC (formerly known as Bayer MaterialScience LLC; Leverkusen, Germany) Industrial Hygiene Laboratory Method. All employees in a SEG were eligible for sampling whether or not they participated in the study.

TWA Exposures

A method was developed to combine Plant/SEGs that had been determined using job titles and professional judgment into data-derived cross-facility SEGs (SuperSEGs), which are comprised of one or more Plant/SEGs. For example, Plant/SEGs included TDI loading of trucks or railcars, TDI field unit operations, and maintenance in the TDI unit. A total of 1594 TWA air samples collected during the study were used to represent exposures for participants in each SEG. To develop the SuperSEGs, the TWA exposure results, without regard to the use of respirators for each Plant/SEG, were categorized into one of the following groups: less than 0.1 ppb; 0.1 to <0.5 ppb; 0.5 to <2 ppb; 2 to <5 ppb; and at least 5 ppb. The bounding categories (<0.1 and 5 ppb) were chosen because 0.1 ppb is approximately the limit of quantification (LOQ), and 5 ppb was the 8-hour TWA-threshold limit value (TLV)[®] at the time of this study.

Cumulative Exposures

Cumulative TWA exposure estimates for individuals were developed on the basis of the log means for the TWA exposure clusters and the length of exposure.¹⁹

Peak Exposures

The estimated 95th percentiles for the TWA exposures were used as an index for the potential peak exposures. The 95th percentile for the TWA ("ml95") was determined for each worker by assigning that worker's highest estimate of the 95th percentile among the Plant/SEGs in which the worker was employed. It was calculated using a censored regression model, assuming a lognormal distribution.

A linear mixed-effects model approach was also used to analyze the longitudinal spirometry data.²⁰ The health outcome variable was the repeated measurement of FEV₁. Multiple factors potentially affecting the measurements of FEV₁ were evaluated as fixed (time-independent) covariables, including baseline age, height, weight, gender, race/ethnicity, plant (Plant A, B, or C), and smoking status. Also evaluated in the mixed effects model were time-dependent covariables, including the interval years from the initial test to each follow-up test, the individual's estimated cumulative TWA exposure from the initial test to each follow-up testing date,¹⁹ and the change from baseline in body weight, with values recorded at the time of each test.

Mixed-model methodology offers additional capabilities in analyzing longitudinal data. Historically, missing data have caused serious problems in the statistical analysis of repeated measures, but such problems do not generally arise with the mixed-model approach, as long as the missing data are random.²⁰ In this study, 197 participants had from 1 to 12 tests in 1 to 6 years of follow-up; and the interval between two tests also varied. However, we did not detect any patterns or specific reasons for missing results. Most absences were not due to health problems and it appeared that failure to attend a health survey was a random event, as stated in the study by Cassidy et al (L. Cassidy, B. Doney, M.L. Wang, et al, in preparation) SAS PROC MIXED provides a rich assortment of covariance structures, including those applicable to unequally spaced data.²¹

The MIXED model procedure was fitted using the pure RANDOM effective statement. Mixed-model methods also permit modeling the covariance structure of the data, which is especially important for analysis of repeated measures. The selection of the appropriate type of covariance structure was accomplished by choosing the smallest Akaike Information Criterion (AIC) after fitting models with alternative covariance structures.²² The final MIXED model procedure was fitted using an unstructured covariance to account for random variation between individuals in the intercept and slope (the longitudinal rate of change in FEV₁ obtained from the mixed models for repeated measurements). This structure specifies an intersubject random effect for differences between individuals.

Two additional mixed models were performed, the first including only white males, and the second model including an addition of a dichotomous marker variable for overweight [body mass index (BMI) ≥ 25 kg/m², yes or no]²³ to further explore the association between weight gain and the decline in FEV₁. An interaction was evaluated in white males regarding being overweight at the time of the spirometry test and the effect of weight gain on FEV₁.

RESULTS

Of the 197 participants, there were 18 participants with one test, 19 with two, 16 with three, 22 with four, 24 with five, 34 with six, 37 with seven, 19 with eight, four with nine, two with 10, and two with 12 tests. The mean number of tests for each participant in this study was 5.1. There were 1007 valid spirometry test results included in the data analysis (45 tests for 12 females, 962 tests for 185 males). Years of follow-up ranged from less than 1 to 6 years, with an average follow-up time of 3.6 years.

Table 1 summarizes the population characteristics and spirometry indices at the initial test by gender. The average age at the initial spirometry test was approximately 42 years. The age ranged from 21 to 62 years at the initial test and from 24 to 67 years at the final test (Table 2). Approximately 64% of the workers were never smokers. The means of %Ref FEV₁ and %Ref FVC at initial and final tests for males and females were all greater than 90% (Table 2). When compared with the mean %Ref FEV₁ (98%) for the U.S. general population, the TDI cohort's initial (102%) and final (99%) mean %Ref FEV₁ were significantly higher for females. The initial mean %Ref FVC was significantly higher than the U.S. general population (100%) and the final mean %Ref FVC was significantly lower. In males, the mean %Ref FEV₁ and FVC were 94% and 93% at the initial test and 93% and 91% at the final test and were significantly lower than the 96% and 99% for the U.S. population. The %Ref FEV₁/FVC ratio was significantly higher among TDI study participants for both females and males. The mean BMI for the TDI study population was significantly lower than the U.S. population (Table 2). Additional comparisons between the TDI study cohort and the U.S. population were made, stratified by both age and smoking for white males only. The results were very similar to the whole TDI study cohort, which are presented in Table 3.

The comparisons of spirometry indices were also made within the TDI cohort, by age group, smoking status, and among four TDI exposure groups by quartiles of ml95. The difference among age groups was as expected. Smoking and TDI exposure effects were detected, but were not statistically significant. The comparisons of never versus ever smokers for mean %Ref FEV₁, FVC, and FEV₁/FVC were 94%, 93%, and 101% versus 94%, 92%, and 102% at the initial test, and 94%, 93%, and 101% versus 93, 91, and 102% at the final test. None of these differences were statistically significant. When comparing the mean %Ref of spirometry indices between the workers in the highest exposure group ("ml95" 75th percentile) versus others, or among four groups by the quartiles of the TDI exposure variable "ml95," the differences were in the direction of an exposure effect, but none of these were significant (data not shown).

The comparison of prevalence of spirometry abnormalities between the TDI cohort and NHANES 2007 to 2010 is summarized in Table 4. The proportion of overall abnormal spirometry for male TDI study participants was significantly higher than the U.S. general population. However, the further categorization of patterns of abnormality showed that the TDI cohort had significantly lower prevalence of obstructive pattern and higher prevalence of restrictive pattern. The prevalence of obstructive and restrictive pattern of spirometry abnormality was similar in never versus ever smokers in the TDI cohort with 0.8% and 1.4% for obstructive and 12.6% and 11.4% for restrictive at the initial test; and 0.8% and 0.0%, and 16.5% and 15.7% at the final test, respectively.

FEV₁ slope calculated by simple linear regression for 160 participants with at least three tests averaged -27.6 mL/year for males ($n=151$) and -25.8 mL/year for females ($n=9$). The mean follow-up years was 3.9 (range: 1 to 6 years); the mean frequency of tests was 5.9 (range: 3 to 12 observations). Comparisons of slope between never and ever smokers and among four groups of quartiles of TDI exposures were not statistically significant.

Participants whose initial age was less than 30 versus at least 30 years, the slope was -21 versus -33.3 mL/year ($P=0.0003$) (data not shown).

The parameter estimates and P values obtained from the mixed-effects model analysis for the whole cohort including 178 participants (168 males and 10 females) who had at least two test results (987 observations in total) are summarized in Table 5. The initial age, height, and weight were significantly related to the absolute value of FEV₁, as was the spirometry testing position (sitting or standing), and the time-dependent covariable of weight gain. The initial level of FEV₁ differed by race/ethnicity and gender, with black participants demonstrating significantly lower values than white and Hispanic participants. Although females values were lower than males, there was not enough power to detect statistically significant differences (female: $n=10$ with 43 observations). The effect of smoking (never vs ever), and the time-dependent covariable of TDI cumulative exposure up to the time of spirometry testing, showed a trend toward declines in FEV₁; however, these did not reach statistical significance. The parameter estimates indicate that a 1-year increase in initial age corresponded to an average 22.6mL decrement in FEV₁ (age effect estimated cross-sectionally), while a 1-year increase in follow-up interval corresponded to an average 31.4mL decline in FEV₁ (age effect estimated longitudinally), after controlling for initial age, height, weight, gender, race/ethnicity, plant, testing position, smoking status, change in body weight, and cumulative exposure. An additional model including only white males ($n=118$ with 686 observations) indicated that the age effect was 24.5 and 27.7 mL/year, cross-sectionally and longitudinally, respectively, after controlling for multiple factors (Table 6).

The mean BMI for the study population as a whole was significantly lower than the U.S. general population (Table 2). At the initial and final testing, the proportion of workers with a BMI less than 25 kg/m², 25 to 29, and at least 30 (categorized as normal, overweight, and obese) was about 44%, 35%, and 21% at initial; and 43%, 30%, and 26% at final spirometry test, respectively. The study population had a higher percentage of normal BMI and lower percentages of overweight and obese workers than the U.S. general population of 32%, 34%, and 34% (using data from NHANES 2007 to 2010 for ages 20 to 69). The study population gained an average of 0.74 kg over the 3.6 years of follow-up. For the study cohort as a whole, a 1 kg increase in weight was associated with an average 11.1mL loss in FEV₁ (Table 5). The additional model including only white males showed similar results that a 1 kg increase in weight was associated with an 11.8mL loss in FEV₁ (Table 6). To further explore the effect of weight gain on FEV₁, an additional mixed-effects model with the addition of a dichotomous marker variable for overweight (BMI ≥ 25 kg/m², yes or no) was investigated. An interaction was evaluated in white males regarding being overweight at the time of the spirometry test and the effect of weight gain on FEV₁. After controlling for the other factors in Table 6, the effect of weight gain on FEV₁ was much greater for white males who were overweight (BMI ≥ 25 kg/m² at the time of the test) than those who were not (-16.6 vs -8.2 mL/kg, $P=0.0184$).

DISCUSSION

The TDI study participants showed a lower mean percentage reference value of FEV₁ and FVC at both initial and final spirometry measurements compared with the U.S. general population (2007 to 2010 NHANES) and also with a recent publication of U.S. coal miners.²⁴ However, the FEV₁/FVC ratio was significantly higher than the above comparison populations. The proportion of overall abnormal spirometry for male TDI study participants was significantly higher than the U.S. general population; whereas the further categorization of patterns of abnormality showed that the TDI cohort had significantly lower prevalence of obstructive pattern and higher prevalence of restrictive pattern, as defined in the Methods. While hypersensitivity pneumonitis is known to occur in response to TDI exposures, a condition that can result in a restrictive pattern on spirometry, no cases were identified in this cohort.^{2-5,25} In addition, variability in measurement technique, as detailed below, seems likely to have affected the results.

In this study, 1007 valid spirometry measurements were analyzed. The correct measurement of height is very important in the calculation of the appropriate reference values and LLN. In the NHANES III survey, standing height was measured without shoes with the subject's back to a vertical backboard. Both heels were placed together, touching the base of the vertical board.¹⁵ In this study, there was variability across plants because the standing height was measured without shoes (as recommended per ATS/ERS guidelines) for only 15% of the tests,¹⁵ 44% with steel toe boots not removed and the shoe heels not subtracted, 41% using the computer records of heights measured at the time of hire and asking for confirmation at the time of testing. We subtracted an estimated shoe heel height of 2 cm from the "height" for those measured with shoes/boots in the database and recalculated the reference value and the LLN to further evaluate the means of spirometry indices and the prevalence of spirometry abnormality. It did not change the main findings, but resulted in 2% reduction in prevalence of overall restrictive abnormality. The testing position also varied; about half of the tests were performed in a sitting position. The prevalence of restrictive pattern abnormality was higher in testing performed in sitting position (16.1% vs 12.1%, $P=0.06$).

The prevalence of restrictive abnormality within the study cohort increased about 4% in males from the initial (12.2%) to the final test (16.2%) (Table 4). Despite the technical limitations described above, a possible effect of TDI exposure should not be ignored considering the increase in prevalence of a restrictive impairment within the study cohort in the population of participants tested using the same position. The lower prevalence of obstructive and mixed abnormalities may partly be due to measurement variability and resulting misclassification. The high proportion of never smokers (64%) in the study population may also play an important role.

The FEV₁ measurements in the study participants were significantly affected by the initial age, height, weight, as well as change in body weight and testing positions. FEV₁ results obtained from different testing positions differed on average by as much as 59 mL, or two times the mean annual longitudinal decline. In the mixed-model analysis, the weight gain parameter is derived from the measured changes (in both FEV₁ and weight) for individual participants over the time interval between the date of the initial spirometry and the date of

each follow-up test. The parameter estimate for weight gain can be interpreted to reflect the reduction in FEV₁ associated with a 1 kg weight gain, with both changes occurring over the same time interval. After adjustment in the model for other significant factors, the FEV₁ effect attributed to a 1 kg weight gain in this study for white males (Table 6) was on average of -11.8 mL/kg, very similar to a previous study of 1884 chemical workers (-2.3 mL/kg).²⁶ An interaction was evaluated in white males regarding being overweight and the effect of weight gain on FEV₁ after controlling for the other factors in Table 6. It was found that the effect of weight gain on FEV₁ was much greater for white males who were overweight (BMI > 25 kg/m²) at the time of the test than those whose BMI was in the normal range (-16.6 vs -8.2 mL/kg, *P*=0.0184).

The current study has several limitations. First, the spirometry reference values and measurements were affected by variations in height measurements and testing posture. Second, no detailed information on smoking history was available to estimate the number of pack-years. A third limitation relates to the wide range of interval between tests, from less than 1 month to 2.8 years; thus, the mixed-model approach was limited to a pure random model and the repeated statement could not be computed appropriately. The American Thoracic Society outlines approaches to evaluating lung function decline.²⁷ They report a typical loss of FEV₁ in adult nonsmokers to be 29 mL/year. A loss of 15% or more after accounting for age-associated loss is considered excessive.^{13,27} Prolonged follow-up is recommended for reliable estimates of the rate of longitudinal change in spirometry measurements in individuals, and only relatively large changes over 1- to 2-year monitoring intervals are confidently identified as abnormal.²⁸⁻³⁰ It has also been reported that a year-to-year decline in FEV₁ greater than 8% or 330mL should be considered abnormal in working populations.³⁰ To effectively interpret serial spirometry results for the purpose of identifying individuals likely to have excessive long-term declines in FEV₁, a previous study investigated the relationship between FEV₁ changes observed during routine spirometry monitoring and subsequent long-term declines using data from a large occupational spirometry monitoring program spanning 30 years.³¹ Their findings indicated that changes in FEV₁ between two tests over 1 to 5 years are significantly associated with long-term lung function declines. In our study, the follow-up duration ranged from 1 to 6 years, with approximately 44% of slopes calculated using repeated measures of FEV₁ in 5 to 6-year intervals. Although the FEV₁ annual decline rate was not excessive for the study population at large, a subset of 19 participants were identified who had at least one annual decline of FEV₁ greater than 350 mL/year or 10%. These are discussed in a companion paper.³² Monitoring change in FEV₁ is useful for assessing adverse respiratory effects in an individual, a yearly decline in FEV₁ greater than 10% might be an early indicator for triggering further evaluation for TDI-induced asthma in the workplace medical monitoring and surveillance program. The prevalence of restrictive pattern on spirometry was not anticipated in this study population based upon TDI asthma pathophysiologic considerations. The prevalence of a restrictive pattern may be partially accounted for by methodologic/testing issues, but it increased over time and constitutes an important focus for further research to evaluate this observation.

Acknowledgments

This study was funded by the American Chemistry Council Diisocyanates Panel.

Support for this work was obtained from the National Occupational Research Agenda, NIOSH, CDC.

We thank the staff who conducted and assisted with spirometry, including Donna Barbay, Michelle Anderson, Jo Doerr, Mary Broussard from BASF Geismar and Courtney Meyer from Covestro LLC (formerly Bayer MaterialScience LLC) Baytown, Lu-Ann Beekman-Wagner of NIOSH for providing spirometry training and conducting quality assurance on the spirometry data throughout the study. Bob Cohen and Eva Hnizdo of NIOSH and Carrie Redlich of Yale School of Medicine provided helpful comments to improve the manuscript.

The authors would also like to acknowledge the original study team, including Edward L. Petsonk, Sue Englehart, Mei Lin Wang, Paul Middendorf, Brent Doney from NIOSH; Pat Conner, William Robert, Gerald Ott, L. Tanner Martinez from BASF Geismar; Jim Chapman, Don Molennar, Raffie Sessa, Raj Dharmarajan, Barbara Cummings from Covestro LLC; Jean Kasakevich, James J. Collins, John Cikalo, Jaime Salazar (deceased) from Dow Freeport; Liz McDaniel and Athena Jolly from Huntsman; Emmett Russell from the International Union of Operating Engineers; and Sahar Osman-Sypher from the American Chemistry Council.

References

1. Fuchs S, Valade P. Clinical and experimental study of some cases of poisoning by desmodur T (1-2-4 and 1-2-6 di-isocyanates of toluene). *Arch Mal Prof.* 1951; 12:191–196. [PubMed: 14830425]
2. Charles J, Bernstein A, Jones B, et al. Hypersensitivity pneumonitis after exposure to isocyanates. *Thorax.* 1976; 31:127–136. [PubMed: 181861]
3. Baur X. Hypersensitivity pneumonitis (extrinsic allergic alveolitis) induced by isocyanates. *J Allergy Clin Immunol.* 1995; 95(5 Pt I):1004–1010. [PubMed: 7751497]
4. Yoshizawa Y, Ohtsuka M, Noguchi K, Uchida Y, Suko M, Hasegawa S. Hypersensitivity pneumonitis induced by toluene diisocyanate: sequelae of continuous exposure. *Ann Intern Med.* 1989; 110:31–34. [PubMed: 2535687]
5. Uranga A, Sánchez-Ortiz M, Morell F, Cruz MJ, Muñoz X. Hypersensitivity pneumonitis due to isocyanates: lung function, clinical and radiological characteristics. *Arch Bronconeumol (English Edition).* 2013; 49:169–172.
6. Gandevia G. Studies of ventilatory capacity and histamine response during exposure to isocyanate vapour in polyurethane foam manufacture. *Br J Ind Med.* 1963; 20:204–209. [PubMed: 14046157]
7. Peters JM, Murphy RLH, Pagnotto LD, Van Ganse WF. Acute respiratory effects in workers exposed to low levels of toluene diisocyanate (TDI). *Arch Environ Health.* 1968; 16:642–647. [PubMed: 5652386]
8. Peters JM. Cumulative pulmonary effects in workers exposed to tolylene diisocyanate. *Proc Roy Soc Med.* 1970; 63:372–375. [PubMed: 5441968]
9. Peters JM, Wegman DH. Epidemiology of toluene diisocyanate (TDI) induced respiratory disease. *Environ Health Perspect.* 1975; 11:97–100. [PubMed: 170078]
10. Omae K. Two-year observation of pulmonary function in workers exposed to low concentrations of toluene diisocyanate. *Int Arch Occup Environ Health.* 1984; 55:1–12. [PubMed: 6098561]
11. Ott MG, Klees IE, Poche SL. Respiratory health surveillance in a toluene di-isocyanate production unit, 1967–97: clinical observations and lung function analyses. *Occup Environ Med.* 2000; 57:43–52. [PubMed: 10711268]
12. Bodner KM, Bums CJ, Randolph NM, Salazar EJ. A longitudinal study of respiratory health of toluene diisocyanate workers. *J Occup Environ Med.* 2001; 43:890–897. [PubMed: 11665458]
13. American Thoracic Society/European Respiratory Society. Standardization of spirometry. *Eur Respir J.* 2005; 26:319–338. [PubMed: 16055882]
14. American Thoracic Society/European Respiratory Society. Interpretative strategies for lung function tests. *Eur Respir J.* 2005; 26:948–968. [PubMed: 16264058]
15. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med.* 1999; 159:179–187.

16. Centers for Disease Control and Prevention. [Accessed August 15, 2015] About the National Health and Nutrition Examination Survey. National Center for Health Statistics. 2014. Available at: http://www.cdc.gov/nchs/nhanes/about_nhanes.htm
17. Centers for Disease Control and Prevention. [Accessed August 15, 2015] Continuous NHANES Web Tutorial. National Center for Health Statistics. 2013. Available at: <http://www.cdc.gov/nchs/tutorials/nhanes/preparing/download/task2.htm>
18. Centers for Disease Control and Prevention. [Accessed August 15, 2015] National Health and Nutrition Examination Survey. National Center for Health Statistics. 2015. Available at: http://www.cdc.gov/nchs/about/major/nhanes/NHANES99_00.htm
19. Middendorf PJ, Miller W, Feeley T, Doney B. Toluene diisocyanate exposure: exposure assessment and development of cross-facility similar exposure groups among toluene diisocyanate production plants. *J Occup Environ Med.* 2017; 59:S1–S12. [PubMed: 29200133]
20. Littell, RC., Milliken, GA., Stroup, WW., Wolfinger, R. SAS® System for Mixed Models. Cary, NC: SAS Institute Inc; 1996. Analysis of Repeated Measures Data; p. 87-134.
21. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. *Stat Med.* 1997; 16:2349–2380. [PubMed: 9351170]
22. Burnham, KP., Anderson, DR. Model selection and inference: a practical information-theoretic approach. New York: Springer-Verlag; 1998. p. 353
23. Jéquier E. Energy, obesity, and body weight standards (Panel summary statements, American Society for Clinical Nutrition). *Am J Clin Nutr.* 1987; 45:1035–1047.
24. Wang ML, Beeckman-Wagner LF, Wolfe AL, Syamlal G, Petsonk EL. Lung function impairment among US underground coal miners, 2005 to 2009: geographic patterns and association with coal workers' pneumoconiosis. *J Occup Environ Med.* 2013; 55:846–850. [PubMed: 23787575]
25. Ott MG. Occupational asthma, lung function decrement, and toluene diisocyanate (TDI) exposure: a critical review of exposure-response relationships. *Appl Occup Environ Hyg.* 2002; 17:891–901. [PubMed: 12495600]
26. Wang ML, Avashia BH, Petsonk EL. Interpreting longitudinal spirometry: weight gain and other factors affecting the recognition of excessive FEV1 decline. *Am J Ind Med.* 2009; 52:782–789. [PubMed: 19670262]
27. Redlich CA, Tarlo SM, Hankinson JL, et al. Official American Thoracic Society technical standards: spirometry in the occupational setting. *Am J Respir Crit Care Med.* 2014; 189:984–994.
28. Burrows B, Lebowitz MD, Camilli AE, Knudson RJ. Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers. *Am Rev Respir Dis.* 1986; 133:974–980. [PubMed: 3717769]
29. Wang ML, Gunel E, Petsonk EL. Design strategies for longitudinal spirometry studies: study duration and measurement frequency. *Am J Respir Crit Care Med.* 2000; 162:2134–2138. [PubMed: 11112127]
30. Wang ML, Petsonk EL. Repeated measures of FEV1 over six to twelve months: what change is abnormal? *J Occup Environ Med.* 2004; 46:591–595. [PubMed: 15213522]
31. Wang ML, Avashia BH, Petsonk EL. Interpreting periodic lung function tests in individuals: the relationship between 1- to 5-year and long-term FEV1 changes. *Chest.* 2006; 130:493–499. [PubMed: 16899850]
32. Collins JJ, Anteau S, Conner PR, et al. Incidence of occupational asthma and exposure to toluene diisocyanate in the United States toluene diisocyanate production industry. *J Occup Environ Med.* 2017; 59:S22–S27. [PubMed: 29200135]

TABLE 1Population Characteristics and Spirometry Indices at the Initial Test by Gender ($n=197$)

	Females ($n=12$)	Males ($n=185$)
Characteristic *		
Age, years	39.8 (5.8, 32–50)	42.1 (9.7, 21–62)
Height, cm	167.0 (7.0, 155–178)	177.4 (6.8, 160–203)
Weight, kg	74.3 (17.1, 46–99)	81.0 (15.2, 43–131)
BMI, kg/m ²	26.7 (6.2, 18–36)	25.7 (4.4, 16–41)
Race/ethnicity		
White (n)	8 (66.7%)	129 (69.7%)
Black (n)	2 (16.7%)	29 (15.7%)
Hispanic (n)	2 (16.7%)	27 (14.6%)
Smoker status		
Ever (n)	4 (33.3%)	66 (64.3%)
Never (n)	8 (66.7%)	119 (35.7%)
Spirometry index *		
FEV ₁ , mL	3157 (370, 2,599–3,688)	3779 (663, 1,535–5,905)
FVC, mL	3850 (512, 3,033–4,873)	4689 (828, 2,289–6,815)
FEV ₁ /FVC	82.3 (4.3, 73.0–87.0)	80.8 (5.3, 57.0–92.0)
%Ref FEV ₁	101.6 (9.9, 88.6–120.6)	93.6 (11.9, 43.7–124.1)
%Ref FVC	101.9 (13.8, 82.1–121.9)	92.5 (11.1, 54.9–120.6)
%Ref FEV ₁ /FVC	99.5 (5.7, 88.2–106.1)	101.1 (6.7, 72.0–12.3)

* Data are presented as mean values (SD, range) unless noted otherwise.

BMI, body mass index; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; %Ref, percent reference value; SD, standard deviation.

TABLE 2

Cross-sectional Comparison of Characteristics and Spirometry Indices Between the TDI Cohort and NHANES 2007–2010

	TDI Cohort (n=197)		NHANES 2007–2010 (n=7,704)*	
	Initial Test	Final Test	Mean (SD)	95% CI
	Mean (SD, range)	Mean (SD, range)		
Males	n=185		n=3,829	
Age, years	42 (9.7, 21–62)	45.3 (10.1, 24–67)	42.7 (0.4)	42.0–43.4
Height, cm	177 (7.0, 152–203) [†]	177.0 (6.7, 160–203) [†]	176.5 (0.2)	176.1–176.9
Weight, kg	81 (15.2, 43–131) [‡]	81.2 (15.3, 42–136) [‡]	89.4 (0.5)	88.3–90.4
BMI, kg/m ²	26 (4.5, 16–41) [‡]	25.9 (4.6, 16–43) [‡]	28.6 (0.1)	28.3–28.9
%Ref FEV ₁	93.7 (12.1, 43.7–124.1) [‡]	92.4 (11.6, 55.1–123.5) [‡]	96.3 (0.4)	95.5–97.1
%Ref FVC	92.5 (11.3, 54.9–120.6)	91.3 (11.5, 60.9–118.1) [‡]	99.0 (0.3)	98.3–99.7
%Ref FEV ₁ /FVC	101.1 (6.7, 72.0–112.3) [†]	101.2 (7.0, 79.5–126.8) [†]	98.1 (0.3)	97.4–98.7
Females	n=12		n=3,875	
Age, years	39.8 (6.0, 32–50) [‡]	41.8 (6.4, 34–53) [‡]	43.1 (0.4)	42.5–44.1
Height, cm	167.0 (7.0, 155–178) [†]	167.0 (7.0, 155–178) [†]	162.9 (0.1)	162.6–163.2
Weight, kg	74.3 (17.1, 46–99) [‡]	75.4 (17.7, 43–99)	76.2 (0.5)	75.2–77.1
BMI, kg/m ²	26.7 (6.2, 18–36) [‡]	27.3 (6.9, 17–38) [‡]	28.7 (0.2)	28.4–29.0
%Ref FEV ₁	101.6 (9.9, 88.6–120.6) [†]	99.3 (12.0, 81.2–120.9) [†]	97.7 (0.3)	97.1–98.4
%Ref FVC	101.9 (13.8, 82.1–121.9) [†]	98.8 (14.0, 80.7–119.2) [‡]	100.3 (0.3)	99.8–100.9
%Ref FEV ₁ /FVC	99.5 (5.7, 88.2–106.1) [†]	100.0 (5.9, 86.3–108.5) [†]	97.7 (0.3)	97.2–98.2

For the comparison made between the mean obtained from TDI study cohort and the corresponding 95% CI obtained from NHANES 2007–2010: if the TDI mean falls into the NHANES 95% CI, there is no significant evidence of difference between the TDI study cohort and the U.S. general population. Otherwise, there is evidence of either significantly higher ([†]) or lower ([‡]) differences between the means of these two populations.

BMI, bodymass index; CI, confidence interval; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; NHANES, National Health and Nutrition Examination Survey; %Ref, percent reference value; SD, standard deviation; TDI, toluene diisocyanate.

* Variance estimation using SAS PROC SURVEYMEANS for a complex survey design. For the purpose of comparing NHANES 2007–2010 with the TDI study, cohort, only NHANES 2007–2010 participants aged 20–69 years were included.

[†] Mean of the TDI cohort is significantly higher than the mean obtained from NHANES 2007–2010.

[‡] Mean of the TDI cohort is significantly lower than the mean obtained from NHANES 2007–2010.

Cross-sectional Comparison of Spirometry Indices Between the TDI Cohort and NHANES 2007–2010 by Smoking Status and Age Group for White Males

TABLE 3

Smoking Status and Spirometry Indices	Age Group*	TDI Cohort (n=129)		NHANES 2007–2010 (n=1,714)	
		Initial Test		Final Test	
		Mean	Mean	Mean	95% CI
Current smoker					
%Ref FEV ₁	20–39	92.4 [‡]	90.8 [‡]	94.8	93.2–96.4
	40–59	91.7 [‡]	90.2	88.5	85.8–91.2
	60–69	—	—	80.4	75.6–85.3
%Ref FVC	20–39	93.5 [‡]	90.3 [‡]	99.5	98.2–100.7
	40–59	91.1 [‡]	87.8 [‡]	96.5	94.1–98.9
	60–69	—	—	92.9	88.7–97.1
%Ref FEV ₁ /FVC	20–39	98.7 [‡]	100.2 [‡]	95.2	93.9–96.6
	40–59	101.1 [‡]	103.1 [‡]	91.4	89.5–93.2
	60–69	—	—	86.6	82.6–90.6
Ex-smoker					
%Ref FEV ₁	20–39	98.4	97.1	98.3	95.5–101.0
	40–59	91.5 [‡]	93.0	95.2	92.9–97.6
	60–69	—	100.2 [‡]	92.9	90.3–95.5
%Ref FVC	20–39	94.4 [‡]	94.6 [‡]	100.4	97.8–103.0
	40–59	89.1 [‡]	91.6 [‡]	97.8	95.7–100.0
	60–69	—	94.8 [‡]	97.5	95.4–99.7
%Ref FEV ₁ /FVC	20–39	104.1 [‡]	103.0 [‡]	97.5	95.9–99.1
	40–59	102.7 [‡]	101.3 [‡]	97.3	95.6–98.9
	60–69	—	105.2 [‡]	95.2	93.3–97.1
Never smoker					
%Ref FEV ₁	20–39	97.2	93.9 [‡]	98.0	96.5–99.4

Smoking Status and Spirometry Indices	Age Group*	TDI Cohort (n=129)		NHANES 2007–2010 (n=1,714)	
		Initial Test	Final Test	Mean	95% CI
		Mean	Mean	Mean	95% CI
%Ref FVC	40–59	92.5 [‡]	93.9 [‡]	97.7	96.4–99.0
	60–69	97.5 [‡]	91.6 [‡]	100.0	98.1–101.9
	20–39	95.6 [‡]	95.2 [‡]	99.6	98.5–100.8
	40–59	91.6 [‡]	92.4 [‡]	98.8	97.2–100.3
%Ref FEV ₁ /FVC	60–69	91.7 [‡]	86.3 [‡]	101.9	99.6–104.3
	20–39	101.3 [‡]	98.5	98.2	97.2–99.1
	40–59	100.8 [‡]	101.5 [‡]	98.9	97.6–100.2
	60–69	106.4 [‡]	105.8 [‡]	98.4	97.1–99.6

For the comparison made between the mean obtained from TDI study cohort and the corresponding 95% CI obtained from NHANES 2007–2010: if the TDI mean falls into the NHANES 95% CI, there is no significant evidence of difference between the TDI study cohort and the U.S. general population. Otherwise, there is evidence of either significantly higher ([‡]) or lower ([‡]) differences between the means of these two populations.

CI, confidence interval; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; NHANES, National Health and Nutrition Examination Survey; %Ref, percent reference value; TDI, toluene diisocyanate.

*The number of subjects in the age groups of 20–39, 40–59, and 60–69 was 10, 9, and 0 in Current smokers; 7, 15, and 0 in Ex-smokers; and 35, 50, and 3 in Never smokers at the initial test; and 10, 17, 0; 10, 30, 3; and 37, 82, 8 in the final test; and 260, 195, 54; 126, 198, 148; and 304, 313, 116 in the NHANES 2007–2010 survey, respectively.

[‡]Mean of the TDI cohort is significantly higher than the mean obtained from NHANES 2007–2010.

[‡]Mean of the TDI cohort is significantly lower than the mean obtained from NHANES 2007–2010.

TABLE 4

Comparison of Prevalence of Spirometry Abnormalities Between the TDI Cohort and NHANES 2007–2010

	TDI Cohort (n=197)		NHANES 2007–2010 (n=7,683)*	
	Initial Test	Final Test	N (%)	95% CI
	N (%)	N (%)		
Males	n=185		n=3,819	
Normal	170 (86.3) [‡]	162 (82.2) [‡]	3,376 (89.5)	88.0–91.0
Abnormal	27 (13.7) [†]	35 (17.8) [†]	443 (10.5)	9.0–12.0
Mixed	1 (0.5)	2 (1.0)	45 (1.0)	0.5–1.4
Obstructive	2 (1.0) [‡]	1 (0.5) [‡]	143 (3.8)	3.0–4.6
Restrictive	24 (12.2) [†]	32 (16.2) [†]	255 (5.8)	4.8–6.8
Total	197 (100.0)	197 (100.0)	3,819 (100.0)	
Females	n=12		n=3,864	
Normal	12 (100.0) [†]	11 (91.7)	3,516 (91.3)	90.4–92.1
Abnormal	0 (0.0) [‡]	1 (8.3)	348 (8.7)	7.9–9.6
Mixed	0 (0.0) [‡]	0 (0.0) [‡]	49 (1.2)	0.8–1.7
Obstructive	0 (0.0) [‡]	0 (0.0) [‡]	99 (2.9)	2.3–3.5
Restrictive	0 (0.0) [‡]	1 (8.3) [†]	200 (4.6)	3.7–5.6
Total	12 (100.0)	197 (100.0)	3,864 (100.0)	

For the comparison made between the prevalence obtained from the TDI study cohort and the corresponding 95% CI obtained from NHANES 2007–2010: if the TDI prevalence falls into the NHANES 95% CI, there is no significant evidence of difference between the TDI study cohort and the U.S. general population. Otherwise, there is evidence of either significantly higher ([†]) or lower ([‡]) differences between these two populations.

CI, confidence interval; NHANES, National Health and Nutrition Examination Survey; TDI, toluene diisocyanate.

* Variance estimation using SAS PROC SURVEYFREQ for a complex survey design. For the purpose of comparing NHANES 2007–2010 with the TDI study cohort, only NHANES participants aged 20–69 years were included; 21 with a missing ‘‘height’’ were excluded.

[†]Prevalence of the TDI cohort is significantly higher than the prevalence obtained from NHANES 2007–2010.

[‡]Prevalence of the TDI cohort is significantly lower than the prevalence obtained from NHANES 2007–2010.

TABLE 5

Parameter Estimates (mL) from Fitting a Mixed-effects Model to All FEV₁ Results, 178 Participants and 987 Spirometry Observations*

	Gender	Race/Ethnicity	Plant	Testing Position	Smoking Status	Estimate, mL	SE	P
Intercept, mL						-4249.3	900.5	<0.0001
Initial age, years						-22.6	3.5	<0.0001
Initial height, cm						55.0	5.4	<0.0001
Initial weight, kg						-8.8	2.3	0.0001
Gender	Female					-245.8	149.5	0.1005
Gender	Male					0.00	—	—
Race/ethnicity		Black				-653.7	119.3	<0.0001
Race/ethnicity		White				68.0	101.5	0.5030
Race/ethnicity		Hispanic				0.0	—	—
Plant			A			110.8	78.6	0.1588
Plant			B			-5.9	90.2	0.9478
Plant			C			0.0	—	—
Testing position				Sitting		-59.2	21.0	0.0050
Testing position				Standing		0.00	—	—
Smoking status					Never	20.1	69.7	0.7729
Smoking status					Ever	0.00	—	—
Weight gain, kg						-11.1	1.6	<0.0001
Cumulative exp. ppb.year						-3.8	5.6	0.5022
Time (Interval, year)						-31.4	4.8	<0.0001

SE, standard error; TDI, toluene diisocyanate.

* Model variables included initial test age, height, weight, gender, race/ethnicity, plant, testing position, and smoking status, as well as the time-dependent covariables (values recorded at the time of each test) including change in body weight from the baseline weight, cumulative TDI exposure during study period, and interval since initial test in years.

Parameter Estimates (mL) from Fitting a Mixed-effects Model to All FEV1 Results for White Males, 118 Participants and 686 Spirometry Observations*

TABLE 6

	Plant	Testing Position	Smoking Status	Estimate, mL	SE	P
Intercept, mL				-4690.3	1221.9	0.0002
Initial age, years				-24.5	4.5	<0.0001
Initial height, cm				60.2	7.3	<0.0001
Initial weight, kg				-12.7	2.8	<0.0001
Plant	A			68.0	102.6	0.5080
Plant	B			-78.8	116.6	0.4985
Plant	C			0.00	—	—
Testing position		Sitting		-86.0	26.4	0.0012
Testing position		standing		0.00	—	—
Smoking status			Never	32.9	90.3	0.7156
Smoking status			Ever	0.00	—	—
Weight gain, kg				-11.8	1.9	<0.0001
Cumulative exp, ppb.year				-10.6	7.4	0.1523
Time (Interval, year)				-27.4	5.7	<0.0001

SE, standard error; TDI, toluene diisocyanate.

* Model variables included initial test age, height, weight, gender, race/ethnicity, plant, testing position, and smoking status, as well as the time-dependent covariables (values recorded at the time of each test) including change in body weight from the baseline weight, cumulative TDI exposure during study period, and interval since initial test in years.